medical mutual - ohio pancreatic enzyme coverage update

Coverage Criteria for Pancreatic Enzyme Testing

Serum lipase - covered indications

Covered when ALL of the following are met

Serum lipase coverage: Measurement of serum lipase is covered for individuals presenting with signs and symptoms of acute pancreatitis.N/A

Signs and symptoms listed in Note 1 (epigastric pain, nausea, vomiting, abdominal tenderness, etc.) must be present.

Not covered: routine or redundant lipase

Not covered when ANY of the following apply

Lipase not covered conditions: Measurement of serum lipase is not covered for individuals with an established diagnosis of acute or chronic pancreatitis; when ordered more than once per visit; or for asymptomatic individuals during a general exam without abnormal findings.N/A

These are explicit limitations in the policy.

Not covered: specific tests and biomarkers

Not covered for diagnosis/assessment/prognosis/severity of acute pancreatitis

Tests not covered: Measurement of serum or urine trypsin, trypsinogen, or trypsinogen activation peptide (TAP); measurement of serum or urine amylase except when ordered for analysis of pancreatic cyst fluid; urinary amylase for initial diagnosis; and measurement of biomarkers including C-reactive protein (CRP), interleukin‑6 (IL‑6), interleukin‑8 (IL‑8), and procalcitonin do not meet coverage criteria for the diagnosis, assessment, prognosis, or determination of severity of acute pancreatitis.N/A

Policy cites lack of sufficient published evidence to support coverage for these tests.

General not covered stance for serum lipase outside indications

Other not covered: For all other situations or conditions not described above (i.e., outside the covered indications), measurement of serum lipase does not meet coverage criteria.N/A

Catch‑all exclusion for situations not meeting the specified indications.

Diagnostic testing for acute pancreatitis

Covered when ALL of the following are met

Diagnostic criteria for AP: At least TWO of the following: (1) characteristic abdominal pain consistent with acute pancreatitis; (2) serum amylase or serum lipase ≥ 3 times the upper limit of normal (URL); (3) radiographic evidence of acute pancreatitis on cross‑sectional imaging.>=2 criteria

Per Atlanta classification and recommendations from professional societies such as IAP/APA and AGA.

Preferred enzyme test: Serum lipase is preferred over serum amylase for initial diagnosis of acute pancreatitis due to higher sensitivity and specificity demonstrated across multiple studies.N/A

Multiple cohort and prospective studies summarized in the evidence support lipase superiority.

Severity/prognostic biomarkers

Consider adjunctive testing when assessing severity or prognosis

Adjunctive biomarkers: Biomarkers such as C‑reactive protein (CRP), procalcitonin, interleukin‑6 (IL‑6), interleukin‑8 (IL‑8), lactate dehydrogenase (LDH), and serum cholinesterase have been studied for assessing severity or prognosis in acute pancreatitis; CRP at 48 hours and IL‑6 have shown favorable performance in some studies, but these biomarkers are adjunctive and do not replace clinical scoring systems (e.g., APACHE‑II, BISAP) or imaging.N/A

Use as adjuncts to clinical assessment and validated scoring systems.

Urine trypsinogen-2 dipstick testing

Considerations for UTDT

Urine trypsinogen-2 dipstick: Point‑of‑care urine trypsinogen‑2 dipstick testing (UTDT) has reported variable sensitivity and specificity across studies (examples include sensitivity ~67–94% and specificity ~62.5–95%); while it may be useful as a rapid POC test, limited sensitivity in some series and lack of FDA approval (as of 2023) restrict routine use as a sole diagnostic test.N/A

POC utility noted but sensitivity concerns and regulatory status limit routine adoption.

Diagnostic coverage criteria

Covered when diagnostic criteria for acute pancreatitis are met

AP diagnosis requires at least two criteria: At least TWO of the following must be present for diagnostic coverage: (1) characteristic abdominal pain; (2) biochemical evidence of pancreatitis defined as amylase or lipase ≥ 3 times the upper limit of normal; (3) imaging consistent with acute pancreatitis on cross‑sectional imaging.N/A

This reflects guideline definitions from AGA, ACG, NASPGHAN and Atlanta classification.

Test selection and retesting rules

Testing preferences and repeat testing

Test selection and repetition: Prefer serum lipase over amylase for initial diagnostic testing; do not routinely order both tests. Routine repeat lipase testing to monitor disease course in established acute or chronic pancreatitis is discouraged and may be denied unless there is new clinical suspicion of acute‑on‑chronic pancreatitis.N/A

Consistent with AACC, Choosing Wisely, and CADTH recommendations and minimum retesting interval guidance.

Updated coverage exclusion for serum amylase

Coverage criteria revised based on literature review:

CC3 - Amylase exclusion: Measurement of serum amylase DOES NOT MEET COVERAGE CRITERIA when ordered for anything other than analysis of pancreatic cyst fluid.N/A

This explicit exclusion was added in the 06/04/2025 revision; amylase was removed from prior covered criteria.

Measurement of serum amylase (except when specifically ordered for analysis of pancreatic cyst fluid), urinary amylase for initial diagnosis, and other pancreatic biomarkers such as trypsin/trypsinogen/TAP are identified in the policy as not meeting coverage criteria for diagnosis, assessment, prognosis, or determination of severity of acute pancreatitis. These tests are excluded because the policy states there is insufficient published scientific literature demonstrating that they are required and beneficial for diagnosis and treatment. (See policy items restricting amylase and trypsin-based testing.)

Routine serial or concurrent measurement of amylase and lipase without a clear clinical indication is identified as unnecessary and contributes to excess costs and downstream interventions. Studies cited in the evidence review report frequent repeat daily testing and concurrent ordering (including many unnecessary serial tests) and estimate substantial aggregate costs; the policy therefore designates routine repeat or concurrent testing without justification as not meeting coverage criteria.

The policy states that serum lipase is the preferred initial diagnostic test for suspected acute pancreatitis and that amylase testing is not recommended when lipase is available. Professional recommendations and the AACC guidance cited in the policy discourage ordering both tests because lipase provides superior sensitivity and a longer diagnostic window while concurrent testing increases costs without materially improving diagnostic performance.

Measurement of serum amylase for indications other than analysis of pancreatic cyst fluid is explicitly excluded from coverage. The revision effective 06/04/2025 adds a formal exclusion stating that when amylase is ordered for anything other than pancreatic cyst fluid analysis it DOES NOT MEET COVERAGE CRITERIA.

Use of the listed non-covered tests (including serum/urine amylase outside cyst fluid analysis, urinary amylase for initial diagnosis, trypsin/trypsinogen/TAP, and biomarkers such as CRP, IL-6, IL-8, and procalcitonin) is considered not medically necessary because the policy cites a lack of adequate published evidence demonstrating benefit for diagnosis, assessment, prognosis, or severity determination in acute pancreatitis.

Ordering both amylase and lipase simultaneously as a default (concurrent ordering) or performing repeated daily serial enzyme testing without new clinical findings is discouraged. The policy references studies showing frequent unnecessary serial and concurrent testing and associated costs, and therefore identifies default concurrent ordering or daily serial testing without clinical justification as low-value and not meeting coverage criteria.

Routine repeat lipase testing to monitor disease course in patients with an established diagnosis of acute or chronic pancreatitis is not recommended and may be considered not medically necessary unless there is new clinical suspicion (e.g., suspected acute-on-chronic pancreatitis). CADTH guidance cited in the policy specifically advises against reordering lipase for monitoring established pancreatitis and notes exceptions only when new diagnostic concern exists.

Serum amylase testing for the diagnosis of acute pancreatitis does not meet coverage criteria except when the test is ordered for analysis of pancreatic cyst fluid. The 06/04/2025 revision removed amylase from diagnostic coverage and added an explicit exclusion for serum amylase outside pancreatic cyst fluid analysis.

Procedure Codes and Diagnostic Thresholds

Procedure codes referencedCPT

82150	Amylase
83519	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
83529	Interleukin-6 (IL-6)
83690	Lipase
84145	Procalcitonin (PCT)
86140	C-reactive protein

Enzyme elevation threshold — >3 times upper limit of normal (URL)

Enzyme elevation threshold>3 times upper limit of normal (URL)

Source guidanceAtlanta classification and IAP/APA recommend using 3x URL to define clinically meaningful enzyme elevation.

Clinical applicationUse >3x URL as the biochemical threshold when considering enzyme-based diagnosis of acute pancreatitis.

Diagnostic enzyme threshold — ≥ 3 times upper limit of normal

Diagnostic enzyme threshold≥ 3 times upper limit of normal

Supporting societiesAGA, ACG, NASPGHAN and other guidelines define diagnostic threshold as ≥3x ULN.

Provider Actions, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization and Coverage Application

Prior authorization: Coverage decisions are applied per indication at the time of the request; no blanket prior authorization requirement is specified in this section.

Apply coverage criteria based on the individual’s benefit coverage at time of request.
No separate prior authorization statement included in this section — evaluate requests per indication.

Documentation Required

Documentation Requirements

Document clinical signs, symptoms, and timing to support testing. For diagnosis of acute pancreatitis, documentation should include symptom onset timing and at least one additional diagnostic criterion (abdominal pain consistent with AP, radiographic evidence, or enzyme elevation ≥3× ULN).

Include specific signs/symptoms (see Note 1): epigastric pain, nausea, vomiting, abdominal distention, fever, hypotension, etc.

Clinical and Evidence Background

Acute pancreatitis (AP) is inflammation of the pancreatic tissue. Diagnosis typically requires at least two of three criteria: characteristic upper abdominal pain consistent with pancreatitis; biochemical evidence of pancreatic injury (serum amylase or lipase elevated to approximately ≥ 3 times the upper limit of normal (ULN)); or radiographic evidence of pancreatitis on cross-sectional imaging. Serum lipase is preferred for diagnosis because it is more sensitive and remains elevated longer than amylase, improving the diagnostic window.

Definitions and Diagnostic Thresholds

Acute pancreatitis (AP)

DefinitionInflammation of the pancreatic tissue with variable severity; diagnosis usually requires two of three criteria (abdominal pain, enzyme elevation ≥3x URL, or characteristic imaging).

Clinical courseApproximately 80% of individuals improve within 1–2 weeks; can range from mild to severe with possible complications.

ClassificationRevised Atlanta classification (2012) underpins diagnosis and severity grading of acute pancreatitis.

Serum lipase

Serum lipase descriptionPancreatic lipase increases within 3–6 hours after pancreatic injury and remains elevated for ~1–2 weeks; generally more sensitive and specific than amylase for AP diagnosis.

Diagnostic windowProlonged elevation provides a wider diagnostic window compared with amylase, useful when presentation/testing is delayed.

Policy Revision History

2025-06-04policy_revisionLatest

Amylase was removed from prior covered criteria (CC1 and CC2) and a new explicit exclusion (CC3) was added: measurement of serum amylase does not meet coverage criteria when ordered for anything other than analysis of pancreatic cyst fluid.

Material changes summary: Amylase was removed from diagnostic coverage except for pancreatic cyst fluid analysis. A new explicit exclusion (CC3) was added stating that measurement of serum amylase DOES NOT MEET COVERAGE CRITERIA when ordered for anything other than pancreatic cyst fluid analysis. Several criteria were renumbered to reflect the removal of amylase from prior covered criteria; these revisions became effective 06/04/2025.

OpenPayer

Pancreatic Enzyme Testing for Acute Pancreatitis